Design Therapeutics Stock Today
| DSGN Stock | USD 5.48 0.28 4.86% |
Performance4 of 100
| Odds Of DistressLess than 22
|
Design Therapeutics is selling at 5.48 as of the 21st of November 2024; that is 4.86 percent decrease since the beginning of the trading day. The stock's open price was 5.76. Design Therapeutics has about a 22 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Design Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of October 2024 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of March 2021 | Category Healthcare | Classification Health Care |
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California. The company has 56.62 M outstanding shares of which 2.59 M shares are currently shorted by private and institutional investors with about 16.31 trading days to cover. More on Design Therapeutics
Moving against Design Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Design Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CoFounder | Pratik Shah | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsDesign Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Design Therapeutics' financial leverage. It provides some insight into what part of Design Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Design Therapeutics (DSGN) is traded on NASDAQ Exchange in USA. It is located in 6005 Hidden Valley Road, Carlsbad, CA, United States, 92011 and employs 54 people. Design Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 310.28 M. Design Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 56.62 M outstanding shares of which 2.59 M shares are currently shorted by private and institutional investors with about 16.31 trading days to cover.
Design Therapeutics currently holds about 359.38 M in cash with (58.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Design Therapeutics Probability Of Bankruptcy
Ownership AllocationDesign Therapeutics holds a total of 56.62 Million outstanding shares. Over half of Design Therapeutics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Design Ownership Details
Design Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2024-06-30 | 695.4 K | |
| Millennium Management Llc | 2024-06-30 | 610.8 K | |
| Goldman Sachs Group Inc | 2024-06-30 | 603.7 K | |
| D. E. Shaw & Co Lp | 2024-06-30 | 535.8 K | |
| Jacobs Levy Equity Management, Inc. | 2024-06-30 | 476.3 K | |
| Two Sigma Investments Llc | 2024-06-30 | 402.7 K | |
| Two Sigma Advisers, Llc | 2024-06-30 | 400.1 K | |
| Assenagon Asset Management Sa | 2024-09-30 | 346.2 K | |
| Prescott Group Capital Management Llc | 2024-09-30 | 343 K | |
| Logos Global Management Lp | 2024-06-30 | 10.1 M | |
| Sr One Capital Management, Lp | 2024-06-30 | 6.5 M |
Design Therapeutics Historical Income Statement
Design Stock Against Markets
Design Therapeutics Corporate Management
| Aseem Ansari | CoFounder Advisor | Profile | |
| Sean Jeffries | Chief Officer | Profile | |
| Elizabeth Gordon | Senior Affairs | Profile | |
| Mustapha Parekh | General Counsel | Profile | |
| Joo MD | CEO Pres | Profile | |
| MD FACC | Consulting Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Design Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Design Therapeutics. If investors know Design will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Design Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.85) | Revenue Per Share 0.001 | Return On Assets (0.14) | Return On Equity (0.18) |
The market value of Design Therapeutics is measured differently than its book value, which is the value of Design that is recorded on the company's balance sheet. Investors also form their own opinion of Design Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Design Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Design Therapeutics' market value can be influenced by many factors that don't directly affect Design Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Design Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Design Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Design Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.